READ-POAF Pilot Studies Postoperative Atrial Fibrillation After Cardiac Surgery

This study is currently recruiting participants.
Verified August 2012 by Catharina Ziekenhuis Eindhoven
Sponsor:
Collaborator:
Maastricht University Medical Center
Information provided by (Responsible Party):
Catharina Ziekenhuis Eindhoven
ClinicalTrials.gov Identifier:
NCT01530750
First received: February 8, 2012
Last updated: August 31, 2012
Last verified: August 2012

February 8, 2012
August 31, 2012
March 2012
February 2013   (final data collection date for primary outcome measure)
atrial fibrillation (AF) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
frequency, frequency distribution, and burden of AF
atrial fibrillation (AF) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
frequency, frequencydistribution, and burden of AF
Complete list of historical versions of study NCT01530750 on ClinicalTrials.gov Archive Site
atrial fibrillation (AF) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
frequency, frequency distribution, burden of AF, AF substrate
atrial fibrillation (AF) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
frequency, frequencydistribution, and burden of AF
Not Provided
Not Provided
 
READ-POAF Pilot Studies Postoperative Atrial Fibrillation After Cardiac Surgery
READ-POAF Pilot Study. The Use of the Reveal XT as Device for Postoperative Atrial Fibrillation Detection After Cardiac Surgery

Postoperative atrial fibrillation after coronary artery bypass grafting will be monitored up to 1 year after the procedure by implanting a Reveal XT internal loop recorder two weeks before the surgery. Frequency, burden, and possible risk factors will be described.

During the operation direct contact epicardial mapping will be performed and tissue samples will be collected to identify an electrophysiological and a structural substrate for development of AF.

Background of the study:

Postoperative atrial fibrillation (POAF) after cardiac surgery is a common (1 in 4) complication and associated with morbidity and mortality. Not all episodes of AF are noticed and detected, especially after discharge. several studies have shown high mortality in POAF patients, suggesting a progression in AF frequency.

Objective of the study:

To investigate the real incidence and burden of POAF. Afterwards a risk stratification of POAF is made. To identify a structural and electrophysiological substrate for the development of POAF and new onset AF during follow up.

Study design:

140 patients will receive a Reveal device. After 3 and 12 months data will be subtracted from the device. 100 of these patient will undergo additional mapping and tissue biopsies during operation.

Study population:

All patients undergoing cardiac surgery without a history of AF and without a pacemaker will be invited to participate in the study.

Primary study parameters/outcome of the study:

Incidence of POAF until 3 months after CABG.

Secondary study parameters/outcome of the study:

Incidence of POAF until 12 months after CABG. Determine risk factors for early and late POAF. Detect pre-operative (unnoticed) episodes of AF.

Determine a substrate for development of AF.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

There is a small risk of minor complications (hemorrhage and infection of the pocket).The device can be explanted easily if necessary. Ther is a burden of the im- and explantation of the device (local anesthesia, approx. 20 minutes). Patient will have to visit the out-hospital clinic twice.

The operation will be prolonged by 30 minutes due to mapping.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

those patients undergoing cardiac surgery.

Atrial Fibrillation
Not Provided
Post cardiac surgery
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
February 2014
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Undergoing non emergency surgery
  • Sinus rhythm on initial visit

Exclusion Criteria:

  • History of atrial fibrillation
  • Internal pacemaker
Both
60 Years to 90 Years
No
Contact: Sander Bramer, MD +31402398680 sander.bramer@cze.nl
Netherlands
 
NCT01530750
NL37204.060.11
No
Catharina Ziekenhuis Eindhoven
Catharina Ziekenhuis Eindhoven
Maastricht University Medical Center
Principal Investigator: Bart van Straten, MD, PhD CZE
Study Director: Sander Bramer, MD CZE
Principal Investigator: Jos Maessen, MD. PhD Maastricht University Medical Center
Catharina Ziekenhuis Eindhoven
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP